傳港交所(00388.HK)仍未決定新任行政總裁人選
《彭博》引述消息指,港交所(00388.HK)行政總裁李小加於本月底離任,但目前委員會仍未決定繼任人選。
目前候選人包括匯控亞太區銀行業務聯席主管劉哲寧、港交所聯席總裁及首席營運總監戴志堅、加拿大退休金計劃投資委員會首席執行官Mark Machin、前摩根大通銀行家Philip Zhai、銀行家Wilfred Yiu。
消息指,港交所希望新行政總裁可有與中國工作的信心,同時具備豐富的國際背景。
據報道指,李小加的離任,與港交所主席史美倫有關,因兩人關係緊張,李小加較隨性,部份重要議題未有及早知會董事會,因而引起不滿。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.